Recombinant human VEGF-C increases dural lymphangiogenesis and eliminates both soluble and insoluble Aβ in Alzheimer’s disease (AD) models, which also provides fresh suggestions for AD treatments [182]. The gene discussed is VEGFC; the disease is early-onset autosomal dominant Alzheimer disease.